argenx (NASDAQ:ARGX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of argenx (NASDAQ:ARGX) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

A number of other equities research analysts have also recently commented on the company. Wedbush increased their target price on argenx from $144.00 to $170.00 and gave the stock an outperform rating in a research note on Friday, August 2nd. ValuEngine cut argenx from a buy rating to a hold rating in a research note on Thursday, August 1st. Stifel Nicolaus reissued a buy rating and issued a $154.00 target price on shares of argenx in a research note on Thursday, August 1st. Morgan Stanley increased their target price on argenx from $143.00 to $173.00 and gave the stock an overweight rating in a research note on Tuesday, August 6th. Finally, Piper Jaffray Companies increased their target price on argenx from $161.00 to $182.00 and gave the stock an overweight rating in a research note on Thursday, May 23rd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. argenx presently has an average rating of Buy and an average price target of $155.27.

NASDAQ ARGX opened at $136.12 on Thursday. argenx has a 12 month low of $63.81 and a 12 month high of $150.92. The stock has a market cap of $4.33 billion, a P/E ratio of -57.92 and a beta of 1.17. The stock’s fifty day moving average price is $141.94 and its 200-day moving average price is $129.56. The company has a current ratio of 9.37, a quick ratio of 14.29 and a debt-to-equity ratio of 0.01.

Several institutional investors have recently added to or reduced their stakes in ARGX. Artisan Partners Limited Partnership boosted its position in shares of argenx by 143.6% during the first quarter. Artisan Partners Limited Partnership now owns 770,336 shares of the company’s stock valued at $96,169,000 after buying an additional 454,046 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of argenx during the first quarter valued at $27,705,000. FMR LLC boosted its position in shares of argenx by 6.1% during the first quarter. FMR LLC now owns 3,699,956 shares of the company’s stock valued at $461,903,000 after buying an additional 212,904 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of argenx by 5.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,806,592 shares of the company’s stock valued at $538,937,000 after buying an additional 209,848 shares during the last quarter. Finally, Boxer Capital LLC purchased a new stake in shares of argenx during the second quarter valued at $28,316,000. 67.41% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Catch-Up Contributions

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.